Drug Transporter (DT) Information

General Information of DT
DT ID DTD0005
Gene Name SLC22A7
Protein Name Organic anion transporter 2
Gene ID
10864
UniProt ID
Q9Y694
TCDB ID
2.A.1.19.25
3D Structure

Modelled DT Structure

Method: multi-sequence alignment based machine learning

Detail: Structure Info

Synonyms NLT; Novel liver transporter; OAT2; SLC22A7; Solute carrier family 22 member 7; hOAT11; hOAT2
DT Family Major Facilitator Superfamily (MFS)
Organic Cation Transporter (OCT) Family
Tissue Specificity Highly expressed in the liver and, to a lesser extent, in the kidney
Function This sodium-independent transporter mediates the transport of multispecific organic anion. Transport of prostaglandin E2, prostaglandin F2, tetracycline, bumetanide, estrone sulfate, glutarate, dehydroepiandrosterone sulfate, allopurinol, 5-fluorouracil, paclitaxel, L-ascorbic acid, salicylate, ethotrexate, and alpha-ketoglutarate.
Disease(s) Chronic obstructive pulmonary disease [ICD-11: CA22]
Edema associated with congestive heart failure [ICD-11: BD10]
Human immunodeficiency virus infection [ICD-11: 1C62.Z]
Hyperuricaemia [ICD-11: 5C55.Y]
Leukemia [ICD-11: 2A60-2B33]
Pain [ICD-11: MG30-MG7Z]
Peptic ulcer [ICD-11: DA61]
Herpes simplex virus infection [ICD-11: 1F00]
Chlamydia infections [ICD-11: 1C2Z]
Endogenous Substrate(s) Organic anions; 2'-Deoxyguanosine
Variability Data of This Drug Transporter (DT)

Regulatory Variability Data of This DT (VARIDT 3.0)

(α) Microbiota Influence of This DT
Microbiota Influence (MBI)

(β) Post-translational Modification of This DT
Post-translational Modification (PTM)

(γ) Transcriptional Regulation of This DT
Transcriptional Regulation (TSR)

(δ) Epigenetic Regulation of This DT
Epigenetic Regulation (EGR)

(ε) Exogenous Modulation of This DT
Exogenous Modulation (EGM)

Structural Variability Data of This DT (VARIDT 2.0)

(β) Inter-species Structural Differences
Inter-species Structural Differences (ISD)

General Variability Data of This DT (VARIDT 1.0)

(α) Genetic Polymorphisms of This DT
Genetic Polymorphisms of This DT (GPD)

(β) Disease-specific Protein Abundances of This DT
Disease-specific Protein Abundances of This DT (DPAD)

(γ) Species- and Tissue-specific DT Abundances
Species/Tissue-specific Protein Abundances of This DT (S/TPAD)
Molecular Transporting Profile of This DT

Full List of Drug(s) Transported by This DT

 Approved Drug

 Click to Show/Hide the Full List of Drug:          15 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Acyclovir
 Approved Drug Info Shingles 1.00E+91 [1]
Allopurinol
 Approved Drug Info Hyperuricaemia 5C55.Y [2]
Aspirin
 Approved Drug Info Pain MG30-MG7Z [3]
Bumetanide
 Approved Drug Info Edema associated with congestive heart failure BD10 [4]
Dinoprostone
 Approved Drug Info Medical abortion JA00.1 [5]
Entecavir
 Approved Drug Info Chronic hepatitis B infection 1E51.0 [6]
Erythromycin
 Approved Drug Info Pelvic inflammatory disease GA05 [7]
Fluorouracil
 Approved Drug Info Stomach cancer 2B72 [4]
Methotrexate
 Approved Drug Info Leukemia 2A60-2B33 [8]
Paclitaxel
 Approved Drug Info Breast cancer 2C60-2C6Z [4]
Penciclovir
 Approved Drug Info Herpes simplex virus infection 1F00 [9]
Ranitidine
 Approved Drug Info Peptic ulcer DA61 [10]
Tetracycline
 Approved Drug Info Gram-positive & negative bacteria infections 1A00-1H0Z [11]
Theophylline
 Approved Drug Info Chronic obstructive pulmonary disease CA22 [7]
Zidovudine
 Approved Drug Info Human immunodeficiency virus infection 1C62.Z [12]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Indication ICD 11 Ref
Prostaglandin f2Alpha
 Preclinical Drug Info Solid tumours 2D4Z [13]

Endogenous Metabolites (EMs) Handled by This DT

 Endogenous Metabolites (EMs)

 Click to Show/Hide the Full List of EMs:            1 EMs in Total
EM Name PubChem CID Detail Experimental Material Ref
Amino acid unspecific N.A. EM Info Unclear experiment used for identifying this EM [14]

Drug-DT Affinity Assessed by Cell Line

 Approved Drug

 Click to Show/Hide the Full List of Drug:            8 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Bumetanide Approved Drug Info Oocytes-OAT2 Km = 7.52 microM [4]
Dinoprostone Approved Drug Info Proximal tubule (S2) cells-OAT2 Km = 0.713 microM [5]
Erythromycin Approved Drug Info Oocytes-OAT2 Km = 18.5 microM [7]
Fluorouracil Approved Drug Info Oocytes-OAT2 Km = 0.0538 microM [4]
Paclitaxel Approved Drug Info Oocytes-OAT2 Km = 0.1428 microM [4]
Tetracycline Approved Drug Info Proximal tubule (S2) cells-OAT2 Km = 439.9 microM [11]
Theophylline Approved Drug Info Oocytes-OAT2 Km = 12.6 microM [7]
Zidovudine Approved Drug Info Proximal tubule (S2) cells-OAT2 Km = 26.8 microM [12]

 Withdrawn, Discontinued or Preclinical Drug

 Click to Show/Hide the Full List of Drug:            1 Drugs in Total
Drug Name Highest Status Detail Cell Line Affinity Ref
Prostaglandin f2Alpha Preclinical Drug Info Proximal tubule (S2) cells-OAT2 Km = 0.425 microM [13]
References
1 Organic anion transporter 2 (SLC22A7) is a facilitative transporter of cGMP. Mol Pharmacol. 2008 Apr;73(4):1151-8.
2 Isolation, characterization and differential gene expression of multispecific organic anion transporter 2 in mice. Mol Pharmacol. 2002 Jul;62(1):7-14.
3 Identification of multispecific organic anion transporter 2 expressed predominantly in the liver. FEBS Lett. 1998 Jun 12;429(2):179-82.
4 Transport mechanism and substrate specificity of human organic anion transporter 2 (hOat2 [SLC22A7]). J Pharm Pharmacol. 2005 May;57(5):573-8.
5 Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J Pharmacol Exp Ther. 2002 Apr;301(1):293-8.
6 Human organic anion transporter 2 is an entecavir, but not tenofovir, transporter. Drug Metab Pharmacokinet. 2017 Feb;32(1):116-119.
7 Possible involvement of organic anion transporter 2 on the interaction of theophylline with erythromycin in the human liver. Drug Metab Dispos. 2005 May;33(5):619-22.
8 Transport of organic anions across the basolateral membrane of proximal tubule cells. Rev Physiol Biochem Pharmacol. 2003;146:95-158.
9 In vitro studies with two human organic anion transporters: OAT2 and OAT7. Xenobiotica. 2018 Oct;48(10):1037-1049.
10 A species difference in the transport activities of H2 receptor antagonists by rat and human renal organic anion and cation transporters. J Pharmacol Exp Ther. 2005 Oct;315(1):337-45.
11 Human organic anion transporters mediate the transport of tetracycline. Jpn J Pharmacol. 2002 Jan;88(1):69-76.
12 Human organic anion transporters and human organic cation transporters mediate renal antiviral transport. J Pharmacol Exp Ther. 2002 Mar;300(3):918-24.
13 Interaction of human organic anion transporters 2 and 4 with organic anion transport inhibitors. J Pharmacol Exp Ther. 2002 Jun;301(3):797-802.
14 Genetic Regulation of Liver Metabolites and Transcripts Linking to Biochemical-Clinical Parameters. Front Genet. 2019 Apr 17;10:348.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.